AbstractOBJECTIVE: The aim of this study was to evaluate the expression of topoisomerase IIα (TOP2A) in epithelial and stromal cells of ovarian cancer. METHODS: TOP2A expression was analyzed in normal ovarian tissue and in laser-microdissected ovarian tumor epithelial and adjacent stromal cells using quantitative real time RT-PCR (n = 38), RNA in situ hybridization (n =13), and immunhistochemistry (n = 69). Results: TOP2A mRNA was detected by RNA in situ hybridization in all ovarian cancer samples, with stronger hybridization signals in tumor epithelial cells compared to adjacent stromal cells. The same expression pattern was found by immunohistochemistry (P = .0001). Very interestingly, specific changes of TOP2A were found in recurrent ova...
Intrinsic or acquired resistance of human tumors to chemotheraphy is often multifactorial. One of th...
<p>(A) Right, quantification according to nuclear IHC TOP1 expression in ovarian neoplasms compared ...
Recent clinical trials have suggested that patients whose breast tumors overexpress HER2 may derive ...
AbstractOBJECTIVE: The aim of this study was to evaluate the expression of topoisomerase IIα (TOP2A)...
BackgroundTopoisomerase I (TOPO1) and topoisomerase IIα (TOP2A) are specific targets of multiple che...
Background: DNA topoisomerase II enzymes are key targets for the group of anti-tumour agents known a...
To study DNA topoisomerase II alpha (Topo-II alpha) and -beta expression and regulation in human ova...
Quantitative and qualitative aspects of topoisomerase (Topo) I and II were studied in 17 malignant o...
To our knowledge, very few data about the role of Topoisomerase IIalpha (TOPO-IIalpha), an enzyme in...
Topoisomerase IIa (topoIIa) is a key enzyme in DNA replication and a molecular target for many commo...
P-glycoprotein (P-gp) expression and DNA topoisomerase (Topo) II are important variables in multidru...
Background: To investigate the role of a topoisomerase I inhibitor (topotecan) in chemoresistant ova...
Abstract Objective Relapsed epithelial ovarian cancer (EOC) is frequently treated with pegylated lip...
WOS: 000410875900004Purpose: the objective of this study was to evaluate the role of the expression ...
Anthracyclines are frequently used for the treatment of breast cancer and topoisomerase II alpha (TO...
Intrinsic or acquired resistance of human tumors to chemotheraphy is often multifactorial. One of th...
<p>(A) Right, quantification according to nuclear IHC TOP1 expression in ovarian neoplasms compared ...
Recent clinical trials have suggested that patients whose breast tumors overexpress HER2 may derive ...
AbstractOBJECTIVE: The aim of this study was to evaluate the expression of topoisomerase IIα (TOP2A)...
BackgroundTopoisomerase I (TOPO1) and topoisomerase IIα (TOP2A) are specific targets of multiple che...
Background: DNA topoisomerase II enzymes are key targets for the group of anti-tumour agents known a...
To study DNA topoisomerase II alpha (Topo-II alpha) and -beta expression and regulation in human ova...
Quantitative and qualitative aspects of topoisomerase (Topo) I and II were studied in 17 malignant o...
To our knowledge, very few data about the role of Topoisomerase IIalpha (TOPO-IIalpha), an enzyme in...
Topoisomerase IIa (topoIIa) is a key enzyme in DNA replication and a molecular target for many commo...
P-glycoprotein (P-gp) expression and DNA topoisomerase (Topo) II are important variables in multidru...
Background: To investigate the role of a topoisomerase I inhibitor (topotecan) in chemoresistant ova...
Abstract Objective Relapsed epithelial ovarian cancer (EOC) is frequently treated with pegylated lip...
WOS: 000410875900004Purpose: the objective of this study was to evaluate the role of the expression ...
Anthracyclines are frequently used for the treatment of breast cancer and topoisomerase II alpha (TO...
Intrinsic or acquired resistance of human tumors to chemotheraphy is often multifactorial. One of th...
<p>(A) Right, quantification according to nuclear IHC TOP1 expression in ovarian neoplasms compared ...
Recent clinical trials have suggested that patients whose breast tumors overexpress HER2 may derive ...